Biotech Updates: Acrivon CLIA Lab, Lilly M&A Spree, Defence Radiopharma COO
Aug 17, 2026
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
News Related to AstraZeneca
Related coverage linked through entity extraction aliases.
Pharma Earnings Roundup: Alnylam, Neurocrine, AbbVie, Merck, Roche Miss Expectations
Aug 11, 2026
Several drugmakers saw shares fall after earnings missed expectations. Alnylam's Amvuttra sales disappointed despite growth; Neurocrine's guidance underwhelmed; AbbVie's Imbruvica and Roche's Vabysmo fell short of consensus.
Merck Strengthens Oncology Pipeline as Keytruda Faces 2028 Patent Expiry
Aug 08, 2026
Merck & Co. is bolstering its oncology pipeline with acquisitions like Terns Pharmaceuticals and Cidara Therapeutics, while Keytruda remains the key growth driver. It expects Keytruda peak sales of $35 billion by 2028 and aims to launch 20 new drugs by 2030.
FDA Grants Rolling Review for QTORIN Rapamycin Amid Scrutiny of Expedited Pathways
Jul 29, 2026
FDA granted rolling review for Palvella's QTORIN rapamycin NDA. Also covered: global expedited approval pathways, accelerated approval scrutiny, and multi-regional CDx strategies.
FDA Approves Calquence Plus Venetoclax as First All-Oral Fixed-Duration CLL Regimen
May 18, 2026
US FDA approved Calquence (acalabrutinib) plus venetoclax as the first all-oral, fixed-duration regimen for adults with chronic lymphocytic leukaemia and small lymphocytic lymphoma. Approval based on AMPLIFY phase III trial showing 77% progression-free at three years vs 67% with chemoimmunotherapy. Regimen already cleared in EU, UK, and Canada.
FDA Approves Breztri Aerosphere for Asthma; EU CHMP Recommends Trixeo
Jul 27, 2026
FDA approved AstraZeneca's Breztri Aerosphere for asthma; EU CHMP recommended Trixeo. Phase 3 KALOS/LOGOS trials showed improved lung function and reduced severe exacerbations versus dual therapy.
AstraZeneca Reports Strong Q1 2026 Results; Stock Sees Unusual Options Activity
Aug 03, 2026
AstraZeneca reported strong Q1 2026 results with 8% revenue growth and 12% operating profit growth, driven by its oncology portfolio and pipeline progress. The company also saw unusual options activity and maintained full-year guidance. Key oncology brands including Imfinzi and Enhertu showed double-digit growth.
BostonGene Named 'Overall AI-based Analytics Company of the Year' in 2026 AI Breakthrough Awards
Jul 07, 2026
BostonGene won the "Overall AI-based Analytics Company of the Year" award in the 9th annual AI Breakthrough Awards. Its platform pairs AI with molecular profiling to support oncology drug development decisions.
Amgen Leads Oncology Push With T-Cell Engagers as AI and Organoid Platforms Reshape Drug Development
Jul 19, 2026
Amgen detailed its T-cell engager and precision therapy strategy at Citi's 2026 summit. GT Biopharma, Onco-Innovations, Oncotelic, and Samsung Biologics also advanced AI and organoid platforms in drug development.
FDA Reshapes Drug Approvals, AI Initiative and Delayed Camizestrant Review Impact AstraZeneca
May 27, 2026
The FDA replaced the two-trial approval requirement with a single pivotal trial standard, launched an AI pilot with AstraZeneca and Amgen, and extended the camizestrant review. A key FDA official is departing. AstraZeneca posted $58.74 billion in revenue.
FDA Extends Camizestrant Review, Issues CRL for PT010, and Adopts Single-Trial Approval Policy
May 27, 2026
The FDA extended the review deadline for AstraZeneca's camizestrant and issued a complete response letter for its COPD drug PT010. The agency also adopted a single-pivotal-trial approval policy, while AstraZeneca sold Losec rights to Cheplapharm.
Trump Administration Bars WHO Talks, Pulls $600M, Faces Drug Price Report
May 28, 2026
The Trump administration barred NIAID officials from WHO meetings, reclaimed $600M from four states, and faced a Senate report showing drug prices rising despite deals. New drugs average $353K a year.
AI Reshapes Cardiovascular Medicine: $1.4B+ Investments and New Diagnostics
Jul 10, 2026
AI is transforming cardiovascular medicine: $1.4B+ in investments, a new cardiac biomarker sensor, and stroke-imaging software in 2,500+ hospitals. FDA, EMA, and PMDA are opening clearer regulatory pathways.
AstraZeneca Deepens China Push With COPD Drug License, Lung Cancer Deal and $15bn Investment
Aug 08, 2026
AstraZeneca is expanding in China with a $200m upfront COPD drug license from Sino Biopharmaceutical, a $1.5bn licensing deal for Dizal's Zegfrovy, and a $15bn manufacturing and R&D investment. The deals add revenue-generating assets to its respiratory and oncology portfolios.
Novo Nordisk Partners With OpenAI as AI Drug Discovery Gains Momentum
Jul 07, 2026
Novo Nordisk partners with OpenAI to speed drug discovery, with pilots by 2026. AI is moving beyond hype into pharma R&D, reflected in major collaborations and new FDA guidance.
Genomics-Driven Drug Discovery: AstraZeneca CNV Study, Helix Deal, Quotient Platform
Jul 07, 2026
AstraZeneca published a large-scale CNV analysis in Nature and partnered with Helix for clinico-genomic data. Quotient Therapeutics is using somatic genomics to identify disease-relevant mutations.
Institutional Investors Shift AstraZeneca Positions; Stock Holds 'Moderate Buy' Consensus
Jul 26, 2026
Institutional investors disclosed mixed moves in AstraZeneca plc during recent quarters, with several large funds selling while others initiated new positions. The company beat earnings expectations with $2.58 EPS and $15.29 billion in revenue. Analysts maintain a 'Moderate Buy' consensus with a $211.00 average price target.
AI Drug Discovery Surges: Galux, LG Chem, Cheiron, Peptris Announce Major Deals
Jul 23, 2026
AI-driven drug discovery attracts major investment and partnerships: Galux closes $29M Series B, LG Chem partners with LabGenius on cancer antibodies, Cheiron raises $8M seed, and Peptris secures $7.7M. Galux also teams with AimedBio on BBB-crossing proteins.
CAM Use Tied to Higher Breast Cancer Death Risk; New Molecule Shows Promise Against Triple-Negative Tumors
Jul 29, 2026
A JAMA Oncology study finds breast cancer patients using complementary and alternative medicine face a higher risk of death. A new molecule SU212 shows promise against triple-negative breast cancer, and global breast cancer cases are projected to rise to 3.5 million by 2050.
Life Sciences Financing Roundup: $5.7B Buyout, Juvisé Refinancing, Biotech IPO
Aug 07, 2026
A global investment firm agreed to acquire a medical device maker for $5.7 billion, while Juvisé Pharmaceuticals secured a $652 million refinancing and Pharmacelera raised $7.1 million. A biotech company also completed a $289 million IPO, and the MHRA issued AI guidance.